13D Filing: RA Capital Management and Kalvista Pharmaceuticals Inc. (KALV)

This
Amendment No. 1 amends and supplements the statement on Schedule 13D (the “Statement”) originally filed with the Securities
and Exchange Commission on February 14, 2017 by the Reporting Persons with respect to the Common Stock, $0.001 par value (the “Common
Stock”), of Kalvista Pharmaceuticals, Inc. (the “Issuer”).   Unless
otherwise defined herein, capitalized terms used in this Amendment No. 1 shall have the meanings ascribed to them in the initial
Statement.

Item
3. Source and Amount of Funds or Other Consideration

Item 3 of the Statement is hereby amended
and supplemented as follows:

On October 12, 2017, the Reporting Persons
purchased 850,000 shares of Common Stock of the Issuer for $7,242,000.00. The shares were purchased with working capital.

Item
4. Purpose of Transaction

Item 4 is hereby supplemented as follows:

The Reporting Persons acquired the Common
Stock referred to in Item 3 for investment purposes and not with an intent, purpose or effect of changing control of the Issuer.

Item
5. Interest in Securities of the Issuer

(a) and (b) See Items 7-11 of the cover
pages and Item 2 above.

(c) The following table lists the Reporting
Persons’ transactions in Common Stock that were effected during the sixty day period prior to the filing of this Schedule
13D:

Transaction	Date	No. Shares	Price
Purchase	12-Oct-2017	850,000	$8.50

(d) Not applicable.

(e) Not applicable.

Item
7. Material to Be Filed as Exhibits

Exhibit 1

Joint Filing Agreement by and among the Reporting Persons is incorporated herein by reference to Exhibit 1 to the Schedule 13D filed by the Reporting Persons with the Securities and Exchange Commission on February 14, 2017.